Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427156 | 0.80 | SMN1; SMN2 (0.63) | LMNASMN1; SMN2MAPTSLC1A3SLC1A1 | |
| SCHEMBL7378562 | 0.79 | LMNA (0.65) | LMNASMN1; SMN2MAPTSLC1A3SLC1A1 | |
| SCHEMBL21383878 | 0.79 | HTT (0.50) | LMNASMN1; SMN2MAPTSLC1A3SLC1A1 | |
| SCHEMBL16757568 | 0.79 | HTT (0.53) | LMNASMN1; SMN2MAPTL3MBTL1HTT | |
| SCHEMBL18654075 | 0.79 | SYK (0.48) | LMNASMN1; SMN2MAPTL3MBTL1HTT | |
| SCHEMBL11886701 | 0.79 | SYK (0.54) | LMNASMN1; SMN2MAPTL3MBTL1HTT | |
| SCHEMBL1054435 | 0.79 | SYK (0.48) | LMNASMN1; SMN2MAPTL3MBTL1HTT | |
| SCHEMBL28766687 | 0.79 | SYK (0.48) | LMNASMN1; SMN2MAPTL3MBTL1HTT | |
| SCHEMBL1895297 | 0.78 | HTT (0.58) | LMNASMN1; SMN2MAPTSLC1A3SLC1A1 | |
| SCHEMBL24431454 | 0.78 | HTT (0.46) | LMNASMN1; SMN2MAPTSLC1A3SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035004-B1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8163758-B2 | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity | PARION SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | CACNA1C, CACNA1B, CACNA1G | LMNA 991/4885SMN1; SMN2 1819/4885MAPT 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.